PT  - JOURNAL ARTICLE
AU  - Vivian Salama
AU  - Yimin Geng
AU  - Jillian Rigert
AU  - Clifton D. Fuller
AU  - Amy C. Moreno
AU  - Sanjay Shete
AU  - Cielito C. Reyes-Gibby
TI  - Systematic Review of Genetic Polymorphisms Associated with Acute Pain and Relevant Acute Toxicities Induced by Radiotherapy for Head and Neck Cancer
AID  - 10.1101/2022.11.15.22282359
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.11.15.22282359
4099  - http://medrxiv.org/content/early/2022/11/15/2022.11.15.22282359.short
4100  - http://medrxiv.org/content/early/2022/11/15/2022.11.15.22282359.full
AB  - Background/objective Pain is the most common acute toxicity following radiation therapy (RT) for head and neck cancer (HNC). The multifactorial origin of radiotherapy-induced pain makes it highly challenging to manage in HNC patients. Multiple studies have been conducted to identify different germline genetic variants associated with cancer pain, however few of them focused on RT-induced acute pain. In this systematic review, we summarize potential mechanisms of acute pain after radiotherapy in HNC focusing on oral cavity/oropharyngeal cancer and identify genetic variants associated with radiotherapy-induced acute pain and other relevant acute toxicities.Methods A comprehensive search of Ovid Medline, EMBASE and Web of Science databases using concepts and terms including “Variants”, “Polymorphisms”, “Radiotherapy”, “Acute pain”, “Acute toxicity” published up to February 28, 2022 was performed by two reviewers. Review articles and citations were reviewed manually. The reported SNPs associated with RT-induced acute pain and toxicities were reported, and the molecular function of the associated genes and pathways were described based on genetic annotation using The Human Gene Database; GeneCards.Results A total of 386 articles were identified electronically and an additional 8 articles were included after manual search. 39 articles were finally included. 51 variants were associated with 40 genes, of which 30 % had function in DNA damage response and repair, 25% in inflammatory and immune response, 17.5 % in cell death or cell cycle, and were associated with RT-inflammatory pain and acute mucositis or dermatitis. 4 variants in 4 genes were associated with neuropathy and neuropathic pain. 13 variants in 10 genes and were associated with RT-induced mixed types of post-RT-pain.Conclusion Different types of pain develop after RT, including inflammatory pain (acute mucositis and acute skin reaction); neuropathic pain; nociceptive pain; and mixed oral pain. Genetic variants involved in DNA damage response and repair, cell death, inflammation and neuropathic pathways may affect pain presentation post-RT. These variants could be used for acute pain prediction and personalized pain management in HNC patients receiving RT.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the following: V.S is funded by the American Legion Auxiliary Fellowship in Cancer Research through the The University of Texas MD Anderson UTHealth Houston Graduate School of Biomedical Sciences and 5K12CA088084, Paul Calabresi K12 Scholars Program, 9/1/2020-8/31/2022, $150,077 ($138,960/year). A.K.M is funded by Principal Investigator, 8 months, Pain-directed Pragmatic Automation of Informatics-based Novel Frameworks for Reducing Radiotherapy-associated Effects (PAINFREE), 5K12CA088084, Paul Calabresi K12 Scholars Program, 9/1/2020-8/31/2022, $150,077 ($138,960/year). J. R. is funded by NIDCR 3R01DE028290-02S1 Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authorsHNSCCHead and neck squamous cell carcinomaOC/OPCOral cavity and oropharyngeal cancerHPVHuman papilloma virusRTRadiotherapyQOLQuality of lifeSSBSingle strand breaksDSBDouble strand breaksROSReactive oxygen speciesHNCHead and neck cancerNPCNasopharyngeal cancerILInterleukinsPGProstaglandinsTNFTumor necrosis factorsGyGrayVEGFvascular endothelial growth factor signalingGABAγ-aminobutyric acidNSCLCNon-Small Cell Lung CancerNGFNerve growth factorATPAdenosine triphosphateSNPsSingle nucleotide polymorphismsDDRDNA damage response